Would you recommend chemoimmunotherapy for metastatic anal squamous cell cancer?
Yes. Carboplatin, paclitaxel, and retifanlimab (anti-PD1-antibody) are a preferred, guideline-recommended treatment for metastatic squamous cell cancer of the anus. The efficacy of this regimen was confirmed in the POD1UM-303/InterAACT-2 phase 3 trial, which randomized patients (n=308) to carboplati...
Short answer: Yes. Chemoimmunotherapy is now recommended as the preferred first-line approach for metastatic anal squamous cell cancer, specifically carboplatin/paclitaxel plus a PD-1 inhibitor (retifanlimab), based on phase 3 evidence demonstrating improved survival outcomes over chemotherapy alone...
Anal canal squamous cell cancer (SCC) is a relatively uncommon disease, with approximately 10,000 new cases in the United States annually. Chemoradiation treatment is curative for a significant percentage of patients. The rate of locoregional failure was reported to be 10% to 30%, and th...